News

The Latest Information about i-FACTOR and Cerapedics

Cerapedics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Find out more

Cerapedics Files Final Module of the PMA Application for FDA Approval of a new P-15 Peptide Enhanced Bone Graft for Lumbar Spine Fusion

Find out more

Cerapedics Reinforces Commitment to Level 1 Evidence with Long-Term Results from Six-Year Pivotal IDE Cervical Study Demonstrating 98.6% Spine Fusion Rates in Patients Treated With i-FACTOR®

Find out more

Cerapedics™ Announces Expansion of Headquarters to Support Growth of its Bone Graft Products

Find out more

Cerapedics Appoints Valeska Schroeder Chairman and Chief Executive Officer

Find out more

Cerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft

Find out more

Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery

Find out more

Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease

Find out more

Cerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada

Find out more

Cerapedics Announces Canadian Approval of its next-generation bone graft

Canada will be the first commercial market to launch i-FACTOR®+ Matrix

Find out more